Evaluation of Maternal Serum Sestrin2 Levels in Preeclampsia and their Relationship with the Disease Severity


Background: Preeclampsia (PE) is considered one of the major causes of both maternal and fetal mortality and morbidity. Advances havebeen made on understanding the pathophysiology of this pregnancy‑specific disorder. Sestrin2 (SESN2) is a metabolic regulator protein,whose expression is induced in response to exposure to different adverse effects such as hypoxia, DNA damage, or oxidative stress, thusacting as cytoprotective. Objective: The objective of the study was to investigate the levels of maternal serum SESN2 in preeclamptic anduncomplicated pregnancies and their association with the disease severity. Patients and Methods: This was a case–control study conducted atthe Department of Obstetrics and Gynecology at Al‑Yarmouk Teaching Hospital in Iraq – Baghdad city from the first of March till the end ofNovember 2019. The study included a total of 92 pregnant women, 27 with a healthy pregnancy, 33 with nonsevere PE, and another 32 havingsevere PE. From all participants, blood samples were collected for the evaluation of serum SESN2 levels using enzyme‑linked immunosorbentassay. Results: The mean readings of SESN2 for normal pregnancies were 5.22 ± 1.71 ng/ml which was significantly lower than that for thenonsevere PE group (8.41 ± 1.42 ng/ml), while SESN2 levels were the highest among those with severe PE (16.92 ± 5.15 ng/ml). A negativecorrelation was found between each of GA at delivery, birth interval, and birth weight and the SESN2 level (P = 0.001); while mean arterialpressure positively correlated with SESN2 levels (P = 0.001), the cutoff value for the diagnosis of severe PE was 9.95 ng/ml (sensitivity of93.8% and specificity of 98.8%). Conclusion: Maternal serum SESN2 levels are significantly higher in pregnancies complicated by severePE than nonsevere PE and control groups. It could be a useful biomarker that can help in diagnosing severe PE.